Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Mouse LIMR3/CD300f is a negative regulator of the antimicrobial activity of neutrophils.

Ueno K, Urai M, Izawa K, Otani Y, Yanagihara N, Kataoka M, Takatsuka S, Abe M, Hasegawa H, Shimizu K, Kitamura T, Kitaura J, Miyazaki Y, Kinjo Y.

Sci Rep. 2018 Nov 27;8(1):17406. doi: 10.1038/s41598-018-35699-4.

2.

Identification of inhibitory mechanisms in pseudo-allergy involving Mrgprb2/MRGPRX2-mediated mast cell activation.

Takamori A, Izawa K, Kaitani A, Ando T, Okamoto Y, Maehara A, Tanabe A, Nagamine M, Yamada H, Uchida S, Uchida K, Isobe M, Hatayama T, Watanabe D, Ando T, Ide T, Matsuzawa M, Maeda K, Nakano N, Tamura N, Ikeda K, Ebihara N, Shimizu T, Ogawa H, Okumura K, Kitaura J.

J Allergy Clin Immunol. 2018 Nov 8. pii: S0091-6749(18)31574-4. doi: 10.1016/j.jaci.2018.10.034. [Epub ahead of print]

PMID:
30414859
3.

The Fab fragment of anti-IgE Cε2 domain prevents allergic reactions through interacting with IgE-FcεRIα complex on rat mast cells.

Hirano T, Koyanagi A, Kotoshiba K, Shinkai Y, Kasai M, Ando T, Kaitani A, Okumura K, Kitaura J.

Sci Rep. 2018 Sep 24;8(1):14237. doi: 10.1038/s41598-018-32200-z.

4.

Leukocyte mono-immunoglobulin-like receptor 8 (LMIR8)/CLM-6 is an FcRγ-coupled receptor selectively expressed in mouse tissue plasmacytoid dendritic cells.

Kaitani A, Izawa K, Maehara A, Isobe M, Takamori A, Matsukawa T, Takahashi M, Yamanishi Y, Oki T, Yamada H, Nagamine M, Uchida S, Uchida K, Ando T, Maeda K, Nakano N, Shimizu T, Takai T, Ogawa H, Okumura K, Kitamura T, Kitaura J.

Sci Rep. 2018 May 29;8(1):8259. doi: 10.1038/s41598-018-25646-8.

5.

IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity.

Takamori A, Nambu A, Sato K, Yamaguchi S, Matsuda K, Numata T, Sugawara T, Yoshizaki T, Arae K, Morita H, Matsumoto K, Sudo K, Okumura K, Kitaura J, Matsuda H, Nakae S.

Sci Rep. 2018 Apr 27;8(1):6639. doi: 10.1038/s41598-018-25094-4.

6.

The CD300e molecule in mice is an immune-activating receptor.

Isobe M, Izawa K, Sugiuchi M, Sakanishi T, Kaitani A, Takamori A, Maehara A, Matsukawa T, Takahashi M, Yamanishi Y, Oki T, Uchida S, Uchida K, Ando T, Maeda K, Nakano N, Yagita H, Takai T, Ogawa H, Okumura K, Kitamura T, Kitaura J.

J Biol Chem. 2018 Mar 9;293(10):3793-3805. doi: 10.1074/jbc.RA117.000696. Epub 2018 Jan 22.

PMID:
29358324
7.

Role of the Ceramide-CD300f Interaction in Gram-Negative Bacterial Skin Infections.

Maehara A, Kaitani A, Izawa K, Shiba E, Nagamine M, Takamori A, Isobe M, Uchida S, Uchida K, Ando T, Maeda K, Nakano N, Voehringer D, Roers A, Shimizu T, Ogawa H, Okumura K, Kitamura T, Kitaura J.

J Invest Dermatol. 2018 May;138(5):1221-1224. doi: 10.1016/j.jid.2017.11.025. Epub 2017 Dec 5. No abstract available.

PMID:
29221685
8.

High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.

Kawabata KC, Hayashi Y, Inoue D, Meguro H, Sakurai H, Fukuyama T, Tanaka Y, Asada S, Fukushima T, Nagase R, Takeda R, Harada Y, Kitaura J, Goyama S, Harada H, Aburatani H, Kitamura T.

Leukemia. 2018 Feb;32(2):419-428. doi: 10.1038/leu.2017.227. Epub 2017 Jul 19.

PMID:
28720764
9.

Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment.

Izawa K, Maehara A, Isobe M, Yasuda Y, Urai M, Hoshino Y, Ueno K, Matsukawa T, Takahashi M, Kaitani A, Shiba E, Takamori A, Uchida S, Uchida K, Maeda K, Nakano N, Yamanishi Y, Oki T, Voehringer D, Roers A, Nakae S, Ishikawa J, Kinjo Y, Shimizu T, Ogawa H, Okumura K, Kitamura T, Kitaura J.

Sci Rep. 2017 Jun 27;7(1):4298. doi: 10.1038/s41598-017-04647-z.

10.

Ceramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation.

Shiba E, Izawa K, Kaitani A, Isobe M, Maehara A, Uchida K, Maeda K, Nakano N, Ogawa H, Okumura K, Kitamura T, Shimizu T, Kitaura J.

J Biol Chem. 2017 Feb 17;292(7):2924-2932. doi: 10.1074/jbc.M116.768366. Epub 2017 Jan 10.

11.

Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia.

Honjo A, Nakano N, Yamazaki S, Hara M, Uchida K, Kitaura J, Nishiyama C, Yagita H, Ohtsuka Y, Ogawa H, Okumura K, Shimizu T.

J Allergy Clin Immunol. 2017 Mar;139(3):987-996.e10. doi: 10.1016/j.jaci.2016.05.046. Epub 2016 Jul 16.

PMID:
27555456
12.

Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).

Kitamura T, Watanabe-Okochi N, Enomoto Y, Nakahara F, Oki T, Komeno Y, Kato N, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nishimura K, Hayashi Y, Nagase R, Saika M, Fukushima T, Asada S, Fujino T, Izawa Y, Horikawa S, Fukuyama T, Tanaka Y, Ono R, Goyama S, Nosaka T, Kitaura J, Inoue D.

J Biochem. 2016 Jan;159(1):17-25. doi: 10.1093/jb/mvv114. Epub 2015 Nov 20. Review.

13.

The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection.

Carnec X, Meertens L, Dejarnac O, Perera-Lecoin M, Hafirassou ML, Kitaura J, Ramdasi R, Schwartz O, Amara A.

J Virol. 2015 Oct 14;90(1):92-102. doi: 10.1128/JVI.01849-15. Print 2016 Jan 1.

14.

The Transcription Factor Ehf Is Involved in TGF-β-Induced Suppression of FcεRI and c-Kit Expression and FcεRI-Mediated Activation in Mast Cells.

Yamazaki S, Nakano N, Honjo A, Hara M, Maeda K, Nishiyama C, Kitaura J, Ohtsuka Y, Okumura K, Ogawa H, Shimizu T.

J Immunol. 2015 Oct 1;195(7):3427-35. doi: 10.4049/jimmunol.1402856. Epub 2015 Aug 21.

15.

Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation.

Matsukawa T, Izawa K, Isobe M, Takahashi M, Maehara A, Yamanishi Y, Kaitani A, Okumura K, Teshima T, Kitamura T, Kitaura J.

Gut. 2016 May;65(5):777-87. doi: 10.1136/gutjnl-2014-308900. Epub 2015 Feb 11.

16.

A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.

Togami K, Kitaura J, Uchida T, Inoue D, Nishimura K, Kawabata KC, Nagase R, Horikawa S, Izawa K, Fukuyama T, Nakahara F, Oki T, Harada Y, Harada H, Aburatani H, Kitamura T.

Exp Hematol. 2015 Apr;43(4):300-8.e1. doi: 10.1016/j.exphem.2014.11.011. Epub 2014 Dec 20.

PMID:
25534203
17.

The molecular basis of myeloid malignancies.

Kitamura T, Inoue D, Okochi-Watanabe N, Kato N, Komeno Y, Lu Y, Enomoto Y, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nagase R, Horikawa S, Hayashi Y, Saika M, Fukuyama T, Izawa K, Oki T, Nakahara F, Kitaura J.

Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(10):389-404. Review.

18.

SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.

Inoue D, Kitaura J, Matsui H, Hou HA, Chou WC, Nagamachi A, Kawabata KC, Togami K, Nagase R, Horikawa S, Saika M, Micol JB, Hayashi Y, Harada Y, Harada H, Inaba T, Tien HF, Abdel-Wahab O, Kitamura T.

Leukemia. 2015 Apr;29(4):847-57. doi: 10.1038/leu.2014.301. Epub 2014 Oct 13.

19.

[Molecular basis of hematological malignancies].

Kitamura T, Inoue D, Nakahara F, Okochi N, Kato N, Togami K, Uchida T, Kagiyama Y, Kawabata KC, Nagase R, Horikawa S, Hayashi K, Saika M, Izawa K, Oki T, Chiba S, Harada Y, Harada H, Kitaura J.

Rinsho Ketsueki. 2014 Oct;55(10):1715-23. Review. Japanese. No abstract available.

PMID:
25297732
20.

Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.

Nakahara F, Kitaura J, Uchida T, Nishida C, Togami K, Inoue D, Matsukawa T, Kagiyama Y, Enomoto Y, Kawabata KC, Chen-Yi L, Komeno Y, Izawa K, Oki T, Nagae G, Harada Y, Harada H, Otsu M, Aburatani H, Heissig B, Hattori K, Kitamura T.

Blood. 2014 Jun 19;123(25):3932-42. doi: 10.1182/blood-2013-01-476747. Epub 2014 May 13.

21.

[An inhibitory receptor LMIR3/CD300f recognizes ceramide].

Kitaura J, Izawa K, Kitamura T.

Seikagaku. 2013 Dec;85(12):1071-5. Review. Japanese. No abstract available.

PMID:
24505937
22.

A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition.

Oki T, Nishimura K, Kitaura J, Togami K, Maehara A, Izawa K, Sakaue-Sawano A, Niida A, Miyano S, Aburatani H, Kiyonari H, Miyawaki A, Kitamura T.

Sci Rep. 2014 Feb 6;4:4012. doi: 10.1038/srep04012.

23.

Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.

Uchida T, Kitaura J, Nakahara F, Togami K, Inoue D, Maehara A, Nishimura K, Kawabata KC, Doki N, Kakihana K, Yoshioka K, Izawa K, Oki T, Sada A, Harada Y, Ohashi K, Katayama Y, Matsui T, Harada H, Kitamura T.

Exp Hematol. 2014 May;42(5):369-379.e3. doi: 10.1016/j.exphem.2014.01.009. Epub 2014 Jan 31.

PMID:
24486648
24.

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata KC, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine RL, Abdel-Wahab O, Kitamura T.

J Clin Invest. 2013 Nov;123(11):4627-40.

25.

Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation.

Izawa K, Isobe M, Matsukawa T, Ito S, Maehara A, Takahashi M, Yamanishi Y, Kaitani A, Oki T, Okumura K, Kitamura T, Kitaura J.

J Allergy Clin Immunol. 2014 Jan;133(1):270-3.e1-7. doi: 10.1016/j.jaci.2013.08.008. Epub 2013 Sep 12. No abstract available.

PMID:
24035150
26.

[The shortest isoform of C/EBPβ, Liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model].

Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, Kurokawa M.

Rinsho Ketsueki. 2013 Aug;54(8):749-58. Japanese. No abstract available.

PMID:
24005435
27.

APC(CDH1) targets MgcRacGAP for destruction in the late M phase.

Nishimura K, Oki T, Kitaura J, Kuninaka S, Saya H, Sakaue-Sawano A, Miyawaki A, Kitamura T.

PLoS One. 2013 May 16;8(5):e63001. doi: 10.1371/journal.pone.0063001. Print 2013. Erratum in: PLoS One. 2014;9(3):e89706.

28.

The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.

Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, Kurokawa M.

Blood. 2013 May 16;121(20):4142-55. doi: 10.1182/blood-2011-07-368654. Epub 2013 Apr 1.

29.

Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition.

Takahashi M, Izawa K, Kashiwakura J, Yamanishi Y, Enomoto Y, Kaitani A, Maehara A, Isobe M, Ito S, Matsukawa T, Nakahara F, Oki T, Kajikawa M, Ra C, Okayama Y, Kitamura T, Kitaura J.

J Biol Chem. 2013 Mar 15;288(11):7662-75. doi: 10.1074/jbc.M112.434746. Epub 2013 Jan 31.

30.

The receptor LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide.

Izawa K, Yamanishi Y, Maehara A, Takahashi M, Isobe M, Ito S, Kaitani A, Matsukawa T, Matsuoka T, Nakahara F, Oki T, Kiyonari H, Abe T, Okumura K, Kitamura T, Kitaura J.

Immunity. 2012 Nov 16;37(5):827-39. doi: 10.1016/j.immuni.2012.08.018. Epub 2012 Nov 1.

31.

Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Kagiyama Y, Kitaura J, Togami K, Uchida T, Inoue D, Matsukawa T, Izawa K, Kawabata KC, Komeno Y, Oki T, Nakahara F, Sato K, Aburatani H, Kitamura T.

Int J Hematol. 2012 Nov;96(5):638-48. doi: 10.1007/s12185-012-1207-6. Epub 2012 Oct 25.

PMID:
23097187
32.

[Molecular mechanisms underlying leukemic transformation of myelodysplastic syndromes (MDS) and chronic myelogenous leukemia (CML)].

Kitamura T, Watanabe-Okochi N, Inoue D, Togami K, Uchida T, Kagiyama Y, Kawabata K, Chiba S, Harada Y, Harada H, Kitaura J, Nakahara F.

Rinsho Ketsueki. 2012 Aug;53(8):734-9. Review. Japanese. No abstract available.

PMID:
22975812
33.

MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.

Enomoto Y, Kitaura J, Shimanuki M, Kato N, Nishimura K, Takahashi M, Nakakuma H, Kitamura T, Sonoki T.

Int J Hematol. 2012 Sep;96(3):334-41. doi: 10.1007/s12185-012-1143-5. Epub 2012 Jul 28.

PMID:
22843432
34.

PRAT4A-dependent expression of cell surface TLR5 on neutrophils, classical monocytes and dendritic cells.

Shibata T, Takemura N, Motoi Y, Goto Y, Karuppuchamy T, Izawa K, Li X, Akashi-Takamura S, Tanimura N, Kunisawa J, Kiyono H, Akira S, Kitamura T, Kitaura J, Uematsu S, Miyake K.

Int Immunol. 2012 Oct;24(10):613-23. Epub 2012 Jul 25.

PMID:
22836022
35.

A soluble form of LMIR5/CD300b amplifies lipopolysaccharide-induced lethal inflammation in sepsis.

Yamanishi Y, Takahashi M, Izawa K, Isobe M, Ito S, Tsuchiya A, Maehara A, Kaitani A, Uchida T, Togami K, Enomoto Y, Nakahara F, Oki T, Kajikawa M, Kurihara H, Kitamura T, Kitaura J.

J Immunol. 2012 Aug 15;189(4):1773-9. doi: 10.4049/jimmunol.1201139. Epub 2012 Jul 6.

36.

Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.

Doki N, Kitaura J, Uchida T, Inoue D, Kagiyama Y, Togami K, Isobe M, Ito S, Maehara A, Izawa K, Kato N, Oki T, Harada Y, Nakahara F, Harada H, Kitamura T.

Int J Hematol. 2012 Feb;95(2):167-75. doi: 10.1007/s12185-011-0994-5. Epub 2011 Dec 22.

PMID:
22189847
37.

Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy.

Kashiwakura JC, Ando T, Matsumoto K, Kimura M, Kitaura J, Matho MH, Zajonc DM, Ozeki T, Ra C, MacDonald SM, Siraganian RP, Broide DH, Kawakami Y, Kawakami T.

J Clin Invest. 2012 Jan;122(1):218-28. doi: 10.1172/JCI59072. Epub 2011 Dec 1.

38.

Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.

Oki T, Kitaura J, Watanabe-Okochi N, Nishimura K, Maehara A, Uchida T, Komeno Y, Nakahara F, Harada Y, Sonoki T, Harada H, Kitamura T.

Leukemia. 2012 May;26(5):1038-45. doi: 10.1038/leu.2011.328. Epub 2011 Nov 25.

PMID:
22116551
39.

Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.

Nakamura M, Kitaura J, Enomoto Y, Lu Y, Nishimura K, Isobe M, Ozaki K, Komeno Y, Nakahara F, Oki T, Kume H, Homma Y, Kitamura T.

Cancer Sci. 2012 Jan;103(1):26-33. doi: 10.1111/j.1349-7006.2011.02108.x. Epub 2011 Nov 1.

40.

Adaptive evolution of sexual systems in pedunculate barnacles.

Yusa Y, Yoshikawa M, Kitaura J, Kawane M, Ozaki Y, Yamato S, Høeg JT.

Proc Biol Sci. 2012 Mar 7;279(1730):959-66. doi: 10.1098/rspb.2011.1554. Epub 2011 Aug 31.

41.

Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning.

Shibata-Minoshima F, Oki T, Doki N, Nakahara F, Kageyama S, Kitaura J, Fukuoka J, Kitamura T.

Int J Oncol. 2012 Jan;40(1):93-8. doi: 10.3892/ijo.2011.1173. Epub 2011 Aug 19.

PMID:
21874235
42.

Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.

Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, Haferlach C, Siebert R, Dyer MJ, Asou N, Aburatani H, Nakakuma H, Kitamura T, Sonoki T.

Leukemia. 2011 Dec;25(12):1849-56. doi: 10.1038/leu.2011.166. Epub 2011 Jul 8.

PMID:
21738213
43.

Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.

Kato N, Kitaura J, Doki N, Komeno Y, Watanabe-Okochi N, Togami K, Nakahara F, Oki T, Enomoto Y, Fukuchi Y, Nakajima H, Harada Y, Harada H, Kitamura T.

Blood. 2011 Jan 6;117(1):221-33. doi: 10.1182/blood-2010-02-270181. Epub 2010 Sep 30.

44.

Characterization of leukocyte mono-immunoglobulin-like receptor 7 (LMIR7)/CLM-3 as an activating receptor: its similarities to and differences from LMIR4/CLM-5.

Enomoto Y, Yamanishi Y, Izawa K, Kaitani A, Takahashi M, Maehara A, Oki T, Takamatsu R, Kajikawa M, Takai T, Kitamura T, Kitaura J.

J Biol Chem. 2010 Nov 12;285(46):35274-83. doi: 10.1074/jbc.M110.137166. Epub 2010 Sep 3.

45.

Expression of ADAMTS4 in Ewing's sarcoma.

Minobe K, Ono R, Matsumine A, Shibata-Minoshima F, Izawa K, Oki T, Kitaura J, Iino T, Takita J, Iwamoto S, Hori H, Komada Y, Uchida A, Hayashi Y, Kitamura T, Nosaka T.

Int J Oncol. 2010 Sep;37(3):569-81.

PMID:
20664926
46.

TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury.

Yamanishi Y, Kitaura J, Izawa K, Kaitani A, Komeno Y, Nakamura M, Yamazaki S, Enomoto Y, Oki T, Akiba H, Abe T, Komori T, Morikawa Y, Kiyonari H, Takai T, Okumura K, Kitamura T.

J Exp Med. 2010 Jul 5;207(7):1501-11. doi: 10.1084/jem.20090581. Epub 2010 Jun 21.

47.

AID-induced T-lymphoma or B-leukemia/lymphoma in a mouse BMT model.

Komeno Y, Kitaura J, Watanabe-Okochi N, Kato N, Oki T, Nakahara F, Harada Y, Harada H, Shinkura R, Nagaoka H, Hayashi Y, Honjo T, Kitamura T.

Leukemia. 2010 May;24(5):1018-24. doi: 10.1038/leu.2010.40. Epub 2010 Apr 1.

PMID:
20357822
48.

Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.

Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, Kumano K, Harada Y, Harada H, Kitaura J, Ogawa S, Kurokawa M, Kitamura T, Chiba S.

Blood. 2010 Apr 8;115(14):2872-81. doi: 10.1182/blood-2009-05-222836. Epub 2009 Oct 27.

49.

Evidence that integrin alpha IIb beta 3-dependent interaction of mast cells with fibrinogen exacerbates chronic inflammation.

Oki T, Eto K, Izawa K, Yamanishi Y, Inagaki N, Frampton J, Kitamura T, Kitaura J.

J Biol Chem. 2009 Nov 6;284(45):31463-72. doi: 10.1074/jbc.M109.030213. Epub 2009 Sep 15.

50.

An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells.

Izawa K, Kitaura J, Yamanishi Y, Matsuoka T, Kaitani A, Sugiuchi M, Takahashi M, Maehara A, Enomoto Y, Oki T, Takai T, Kitamura T.

J Immunol. 2009 Jul 15;183(2):925-36. doi: 10.4049/jimmunol.0900552. Epub 2009 Jun 26.

Supplemental Content

Loading ...
Support Center